upadacitinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5346 1310726-60-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • upadacitinib hydrate
  • upadacitinib
  • ABT-494
  • rinvoq
Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.
  • Molecular weight: 380.38
  • Formula: C17H19F3N6O
  • CLOGP: 2.26
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 78.32
  • ALOGS: -3.73
  • ROTB: 4

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2020 PMDA AbbVie GK
Aug. 16, 2019 FDA ABBVIE INC
Dec. 16, 2019 EMA AbbVie Deutschland GmbH & Co. KG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 404.42 29.09 86 1203 10705 46674068
COVID-19 171.27 29.09 48 1241 18527 46666246
Urinary tract infection 53.79 29.09 46 1243 220220 46464553
Herpes zoster 41.85 29.09 25 1264 67847 46616926
Illness 31.24 29.09 12 1277 12212 46672561

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 83.65 38.97 17 294 4512 29947655
COVID-19 42.69 38.97 13 298 17865 29934302

Pharmacologic Action:

SourceCodeDescription
ATC L04AA44 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
MeSH PA D018501 Antirheumatic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D000075242 Janus Kinase Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.85 acidic
pKa2 12.79 acidic
pKa3 3.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
15MG RINVOQ ABBVIE INC N211675 Aug. 16, 2019 RX TABLET, EXTENDED RELEASE ORAL Aug. 16, 2024 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase JAK1 Kinase INHIBITOR IC50 7.33 SCIENTIFIC LITERATURE DRUG LABEL
Tyrosine-protein kinase JAK2 Kinase INHIBITOR IC50 6.92 SCIENTIFIC LITERATURE DRUG LABEL
Tyrosine-protein kinase JAK3 Kinase INHIBITOR IC50 5.63 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
4038662 VANDF
C4308782 UMLSCUI
CHEMBL3622821 ChEMBL_ID
CHEMBL3707269 ChEMBL_ID
58557659 PUBCHEM_CID
D10994 KEGG_DRUG
C000613732 MESH_SUPPLEMENTAL_RECORD_UI
10209 INN_ID
DB15091 DRUGBANK_ID
4RA0KN46E0 UNII
9246 IUPHAR_LIGAND_ID
2196092 RXNORM
321410 MMSL
37314 MMSL
d09350 MMSL
018092 NDDF
789397000 SNOMEDCT_US
789416006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rinvoq HUMAN PRESCRIPTION DRUG LABEL 1 0074-2306 TABLET, EXTENDED RELEASE 15 mg ORAL NDA 29 sections